Targeted Accelerated TMS for Post-Traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) is a highly prevalent and debilitating condition among veterans and active-duty military personnel, with rates as high as 30% in certain combat-exposed populations. Conventional treatments such as prolonged exposure therapy and pharmacotherapy have limited efficacy and high dropout rates, highlighting the need for novel, rapidly effective interventions. Transcranial magnetic stimulation (TMS) has been well established for treatment-resistant depression (TRD). Traditional TMS, which involves 6 to 7 weeks of daily, weekday scalp-targeted treatment, shows open-label response and remission rates of 58.1% and 30%, respectively. However, such protocols may be impractical for military personnel with limited medical leave. A new form of accelerated TMS (aTMS) that involves 10 imaging-guided treatments per day for 5 consecutive days has demonstrated substantial antidepressant benefits within days and response rates of 69% at 1-month follow-up. This protocol has not been tested for PTSD, in part because there was no causally informed brain circuit target. In this study, the investigators will test aTMS for PTSD using a novel PTSD circuit that the investigators have derived.

NCT Number	NCT07245641
Lead Sponsor	Brigham and Women's Hospital Collaborators: Mass General Home Base Program
Conditions	Post Traumatic Stress Disorder (PTSD)
Enrollment	40 participants
Start Date	2025-12-15
Primary Completion	2027-11 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-13